RxDoctor Payments Data

Colleen del Valle, DO

Family Medicine · Minneapolis, MNNPI 1255990198

Payments from drug & device makers

$1,093in general payments, 2019–2025

Across 55 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$198
  • AstraZeneca$161
  • Novo Nordisk$112
  • Pfizer$89
  • Takeda Pharmaceuticals U.S.A., Inc.$67
  • Exact Sciences$60
  • plus $405 from 14 others

What the payments were for

  • Food & beverage$1,093100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,093 in reported general payments places this provider in the 90th percentile of 1,162 family medicine providers in Minnesota.

See all family medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$96,532
Medicare patients
220
Services billed
1,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide74$86,770
OzempicSemaglutide20$41,496
RybelsusSemaglutide16$30,398
FarxigaDapagliflozin Propanediol28$28,701
TrulicityDulaglutide17$25,942
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$24,132
MyrbetriqMirabegron11$15,200
LinzessLinaclotide11$13,280
Atorvastatin Calcium260$3,276
Gabapentin131$2,955
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,658
Levothyroxine Sodium158$1,755
Omeprazole57$1,725
Olmesartan Medoxomil67$1,715
Rosuvastatin Calcium63$1,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$42$112,71291 claims
Novo NordiskOzempic, Rybelsus$112$71,89436 claims
AstraZenecaFarxiga$161$28,70128 claims
GSKTrelegy Ellipta$29$24,13220 claims
Astellas Pharma US IncMyrbetriq$25$15,20011 claims
AbbVieLinzess$198$13,28011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,162 family medicine providers in Minnesota.

Other family medicine in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →